Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
07/2010
07/14/2010CN101773536A Medicament for treating cancers
07/14/2010CN101773532A Carpesium abrotanoides total terpene lactones extract
07/14/2010CN101773526A Production technology of ganoderma lucidum spore powder
07/14/2010CN101773523A Traditional Chinese medicine antimanic drug for treatment of hyperlipemia and preparation thereof
07/14/2010CN101773499A New applications of tetrahydropalmatine
07/14/2010CN101773495A Anti-tumor medicinal composition and application and preparation method thereof
07/14/2010CN101773494A New application of green tea polyphenol
07/14/2010CN101773487A Exotic plant Flaveria bidentis active ingredient chlorogenic acid intercalation hydrotalcite and preparation method thereof
07/14/2010CN101773480A Preparation method of Nnanocrystal preparation containing docetaxelDuoxitasai and method for preparing a freeze-drying agent thereof
07/14/2010CN101773471A Mitoxantrone targeting sustained-release long-circulating nanometer liposome and preparation method
07/14/2010CN101773465A Polymer micelle medicine carrying system using amino acid as stabilizing agent
07/14/2010CN101255190B Use of human midkine protein blocking peptide in preparation of antitumor medicament
07/14/2010CN101244272B Anti-solid tumors pharmaceutical combination containing topological enzyme inhibitor
07/14/2010CN101204521B Peroral Chinese traditional medicine prescription for leukemia
07/14/2010CN101181280B Pirarubicin freeze-dry preparations and preparation method thereof
07/14/2010CN101168597B Hollow polymer sub-micron sphere coated with gold case and preparation method
07/14/2010CN101167718B Rebescensine A powder injection and preparing process thereof
07/14/2010CN101045037B Cationic elaioplast and its adenovirus composition, its preparing method and use
07/14/2010CN101007992B Health white spirit containing beneficial functional component
07/13/2010US7756643 Method for determining the biological effect and/or activity of at least one drug, chemical substances and/or pharmaceutical composition based on their effect on the methylation status of DNA
07/13/2010US7756559 Device for generating a detectable signal based upon antibody/antigen interaction
07/13/2010US7754872 Liposomal phosphodiester, phophorothioate, and p-ethoxy oligonucleotides
07/13/2010US7754855 comprising a full-length human erythropoietin protein joined without an intervening peptide linker to a human immunoglobulin domain; making fusion proteins comprising a cytokine or growth factor fused to an immunoglobulin domain; treating deficient hematocrit; purification
07/13/2010US7754853 Tumor necrosis factors (TNF); site-directed mutagenesis, genetic deletions; monoclonal antibodies with decreased immunogenicity and lymphocyte epitopes; major histocompatibility complex binding ligands; for treatment of rheumatoid arthritis and Crohn's disease
07/13/2010US7754772 (2R)-2,3-bis(nitrooxy)propyl(2S)-2(6-methoxy(2-naphthyl)propanoate, used for treating inflammation, pain and fever; gastrointestinal disorders; wound healing agents; preventing gastrointestinal, renal and/or respiratory toxicities; side effect reduction
07/13/2010US7754751 Preferential inhibition of release of pro-inflammatory cytokines
07/13/2010US7754750 a -5 substituted 1-H,3-H-imidazolidine-2,4-dione such as 5-(2-{[4-(4'-fluoro[1,1'-biphenyl]-4-yl)-1-piperazinyl]sulfonyl}ethyl)-2,4-imidazolidinedione; protease inhibitors, especially metalloelastase (MMP12)
07/13/2010US7754734 Administering one or more rapamycin derivatives (including rapamycin and 40-O-(2-hydroxy)ethyl-rapamycin); lymphocytic leukemia, lymphoma, Epstein-Barr virus, inhibiting graft rejection and metastasis; drug screening
07/13/2010US7754728 Adenine compound and use thereof
07/13/2010US7754716 vatalanib succinate (PTK787) and temozolomide; glioblastomas
07/13/2010US7754713 such as 6-(4-Hydroxy-3,5-dimethylphenyl)-4-(7-methyl-1H-benzimidazol-2-yl)-2H-pyridazin-3-one, used as cyclin-dependent kinase inhibitors, for the treatment of cancer, in particular solid tumors or leukemia; anticarcinogenic agents
07/13/2010US7754709 Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds
07/13/2010US7754682 Blood coagulation factor; nucleotide sequence encodes polypeptide; amino acid sequence differs in 1-15 amino acid residues and comprises an introduced in vivo N-glycosylation site; substitution V253N; coagulation related disorders
07/13/2010US7754676 Cancer and viral infections vaccines; increased immunogenicity
07/13/2010US7754449 Human papilloma virus treatment
07/13/2010US7754228 Cytotoxic T-cell epitopes from Chlamydia
07/13/2010US7754220 Continuously administering to a male animal a polypeptide havingan amino acid sequence to promote the activity of Metastin, (kisspeptin-54), an endogenous ligand for G protein-coupled receptor; promoters of fertility, ovulation; treating hormone-sensitive cancers; endometriosis; drug screening
07/13/2010US7754219 by binding a target antigen (such as a protein) to a transport factor that contains a fragment of a bipartite protein exotoxin, but not the corresponding protective antigen
07/13/2010US7754206 reducing the size of a solid tumor expressing CD44 using Notch4 antagonist
07/13/2010CA2522148C Thorium-227 for use in radiotherapy of soft tissue disease
07/13/2010CA2505910C Imidazoquinoline derivatives as adenosine a3 receptor ligands
07/13/2010CA2481365C Occlusive composition comprising a poly (2-cyanoacrylate) monomer
07/13/2010CA2448303C Biologically active methylene blue derivatives
07/13/2010CA2446820C Novel pyrrole derivatives as pharmaceutical agents
07/13/2010CA2444244C Methods of synthesizing acylanilides including bicalutamide and derivatives thereof
07/13/2010CA2440979C Spirolaximes for use in the treatment of pathologies that respond to ppar-.gamma. receptor activation
07/13/2010CA2430539C Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
07/13/2010CA2423488C Thermogelling biodegradable aqueous polymer solution
07/13/2010CA2347713C Contulakin-g, analogs thereof and uses therefor
07/08/2010WO2010078526A1 Anti-lymphotoxin antibodies
07/08/2010WO2010078427A1 Substituted pyrazolo [3, 4-b] pyridine compounds
07/08/2010WO2010078421A1 Substituted 5,6-dihydro-6-phenylbenzo[f] isoquinolin-2-amine compounds
07/08/2010WO2010078408A1 Heteroaryl compounds useful as raf kinase inhibitors
07/08/2010WO2010078307A1 Spiro-oxindole-derivatives as sodium channel blockers
07/08/2010WO2010078294A1 Method of preparing (+)-1,4-dihydro-7-[(3s,4s)-3methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
07/08/2010WO2010077894A2 Methods of inhibiting quiescent tumor proliferation
07/08/2010WO2010077758A1 Compounds useful for inhibiting chk1
07/08/2010WO2010077693A2 Method for identifying agents for inhibiting cell motility and invasiveness
07/08/2010WO2010077686A1 Isoindolinone and related analogs as sirtuin modulators
07/08/2010WO2010077663A2 Substituted tetracyclic 1h-indeno (1,2-b) pyridine-2 (5h)-one analogs thereof and uses thereof
07/08/2010WO2010077634A1 Anti-pd-l1 antibodies and their use to enhance t-cell function
07/08/2010WO2010077613A1 Modulators of toll-like receptors
07/08/2010WO2010077589A2 Stat3 inhibitors and therapeutic methods using the same
07/08/2010WO2010077530A1 C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof
07/08/2010WO2010077310A2 Amide derivatives of ethacrynic acid
07/08/2010WO2010077168A1 Drug made from stem cells with reprogrammed cell signaling, method for producing said preparation and the use thereof
07/08/2010WO2010076896A1 Prophylactic/therapeutic agent for cancer
07/08/2010WO2010076879A1 Sulfated c-glycoside, method for isolating same and method for synthesizing same
07/08/2010WO2010076813A1 Thienopyridines as pharmacologically active agents
07/08/2010WO2010076764A1 Irreversible egfr inhibitor compounds with antiproliferative activity
07/08/2010WO2010076323A1 Use of ammonium chloride in therapy
07/08/2010WO2010076238A1 Substituted quinazoline compounds
07/08/2010WO2010076034A1 Toluidine sulfonamides and their use as-inhibitors
07/08/2010WO2010076033A1 Toluidine sulfonamides and their use
07/08/2010WO2010075869A1 Toluidine sulfonamides and their use
07/08/2010WO2010075770A1 A recombinant fusion protein, the preparation method and use thereof
07/08/2010WO2010075611A1 Composition comprising proanthocyanidin, proteolytic enzyme and aloe vera/agave species substance
07/08/2010WO2010051634A9 Human progenitor t-cells
07/08/2010WO2010049451A3 C-glycosidic analogues of alpha-galactosylceramids having immunostimulating and immunoregulating properties
07/08/2010WO2010048452A3 Polycyclic compounds and methods related thereto
07/08/2010WO2010045573A3 Tumor vaccine
07/08/2010WO2010042933A9 Inhibition and treatment of prostate cancer metastasis
07/08/2010WO2010042684A4 Pyrrolotriazine kinase inhibitors
07/08/2010WO2010039668A3 Inhibitors of cyclin kinase inhibitor p21
07/08/2010WO2010028051A3 Substituted heterocyclic mercaptosulfonamide metalloprotease inhibitors
07/08/2010WO2010021750A3 Methods and compositions for administration of 3-halopyruvate and related compounds for the treatment of cancer
07/08/2010WO2010007169A9 Pharmaceutical compositions comprising lignans and their derivatives for treating hyperplastic diseases
07/08/2010WO2009129361A3 Bryostatin analogues and methods of making and using thereof
07/08/2010WO2009024631A9 A combination of inhibitors of tgfbeta-1 and matrix metalloproteins for use in the treatment of bone metastases, bone resorption and hypercalcaemia
07/08/2010US20100174076 Coumarin derivatives useful as tnf alpha inhibitors
07/08/2010US20100174056 Recombinant tumor specific antibody and use thereof
07/08/2010US20100173990 Transglutaminase Inhibitor Comprising Chlorogenic Acid And A Method For Producing Thereof
07/08/2010US20100173988 Oxaliplatin active substance with a very low content of oxalic acid
07/08/2010US20100173985 Polyphenol proteasome inhibitors, synthesis, and methods of use
07/08/2010US20100173978 Human mini-antibody cytotoxic for tumor cells which express the erbb2 receptor
07/08/2010US20100173972 Methods and uses related to rhbdl4
07/08/2010US20100173967 Use of spiro-oxindole compounds as therapeutic agents
07/08/2010US20100173955 4-substituted phenoxyphenylacetic acid derivatives
07/08/2010US20100173954 Treatment of cancers having resistance to chemotherapeutic agents
07/08/2010US20100173953 4-[4-(amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate
1 ... 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 ... 2211